TISIDB

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	PF00084 Sushi repeat (SCR repeat)
Function	Receptor for complement C3Dd, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU (PubMed:7753047). Participates in B lymphocytes activation (PubMed:7753047). ; FUNCTION: (Microbial infection) Acts as a receptor for Epstein-Barr virus.

> Gene Ontology [ TOP ]
Biological Process	GO:0002250 adaptive immune response GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002430 complement receptor mediated signaling pathway GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002455 humoral immune response mediated by circulating immunoglobulin GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006956 complement activation GO:0006958 complement activation, classical pathway GO:0006959 humoral immune response GO:0016064 immunoglobulin mediated immune response GO:0019058 viral life cycle GO:0019724 B cell mediated immunity GO:0030098 lymphocyte differentiation GO:0030183 B cell differentiation GO:0030260 entry into host cell GO:0032943 mononuclear cell proliferation GO:0042100 B cell proliferation GO:0042113 B cell activation GO:0044409 entry into host GO:0046651 lymphocyte proliferation GO:0046718 viral entry into host cell GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0070661 leukocyte proliferation GO:0072376 protein activation cascade
Molecular Function	GO:0001618 virus receptor activity GO:0001848 complement binding GO:0004875 complement receptor activity
Cellular Component	GO:0043235 receptor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04610 Complement and coagulation cascades hsa04640 Hematopoietic cell lineage hsa04662 B cell receptor signaling pathway
Reactome	-

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CR2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.51	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CR2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.41	0.519
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.413	0.175
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.335	0.698
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.163	0.802
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.768	0.543
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.598	0.679
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.946	0.0752
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	2.193	0.15
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	2.033	0.227
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.986	0.12
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.307	0.687
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.071	0.858

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CR2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	6.8	0.6	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	3.7	9.5	0.388
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	22.7	7.7	15	0.377
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CR2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CR2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CR2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CR2
Name	complement component (3d/Epstein Barr virus) receptor 2
Aliases	CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location	1q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CR2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CR2